

Original Article

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability

Angel L.M. de Francisco¹, Michael Leidig², Adrian C. Covic³, Markus Ketteler⁴, Ewa Benedyk-Lorens⁵, Gabriel M. Mircescu⁶, Caecilia Scholz⁷, Pedro Ponce⁸ and Jutta Passlick-Deetjen⁷

¹Hospital Marques de Valdecilla, Universidad de Cantabria, Santander, Spain, ²Kuratorium für Heimdialyse, Nuernberg, Germany, ³University of Medicine Gr T Popa Iasi, Iasi, Romania, ⁴Klinikum Coburg, Coburg, Germany, ⁵Fresenius NephroCare, Krakow, Poland, ⁶Clin. Nephrol. Hosp. Dr. Carol Davila, Bucharest, Romania, ⁷Fresenius Medical Care, Bad Homburg, Germany and ⁸Almada-NMC-Centro Médico Nacional, Lisbon, Portugal

Correspondence and offprint requests to: Angel L.M. de Francisco; E-mail: angelmartindefrancisco@gmail.com

Abstract

Background. Phosphate binders are required to control serum phosphorus in dialysis patients. A phosphate binder combining calcium and magnesium offers an interesting therapeutic option.

Methods. This controlled randomized, investigator-masked, multicentre trial investigated the effect of calcium acetate/magnesium carbonate (CaMg) on serum phosphorus levels compared with sevelamer hydrochloride (HCl). The study aim was to show non-inferiority of CaMg in lowering serum phosphorus levels into Kidney Disease Outcome Quality Initiative (K/DOQI) target level range after 24 weeks. Three hundred and twenty-six patients from five European countries were included. After a phosphate binder washout period, 255 patients were randomized in a 1:1 fashion. Two hundred and four patients completed the study per protocol (CaMg, $N = 105$; dropouts $N = 18$; sevelamer-HCl, $N = 99$; dropouts $N = 34$). Patient baseline characteristics were similar in both groups.

Results. Serum phosphorus levels had decreased significantly with both drugs at week 25, and the study hypothesis of CaMg not being inferior to sevelamer-HCl was confirmed. The area under the curve for serum phosphorus ($P = 0.0042$) and the number of visits above K/DOQI (≤ 1.78 mmol/L, $P = 0.0198$) and Kidney disease: Improving global outcomes (KDIGO) targets (≤ 1.45 mmol/L, $P = 0.0067$) were significantly lower with CaMg. Ionized serum calcium did not differ between groups; total serum calcium increased in the CaMg group (treatment difference 0.0477 mmol/L; $P = 0.0032$) but was not associated with a higher risk of hypercalcaemia. An asymptomatic increase in serum magnesium occurred in CaMg-treated patients (treatment difference 0.2597 mmol/L, $P < 0.0001$). There was no difference in the number of patients with adverse events.

Conclusion. CaMg was non-inferior to the comparator at controlling serum phosphorus levels at Week 25. There was no change in ionized calcium; there was minimal increase in total serum calcium and a small increase in serum magnesium. It had a good tolerability profile and thus may represent an effective treatment of hyperphosphataemia.

Keywords: calcium acetate; haemodialysis; magnesium carbonate; phosphate binder; safety parameters

Introduction

In patients with chronic kidney disease stage 5 (CKD 5), increasing evidence links inadequate serum phosphorus control to higher morbidity and mortality [1–6]. As a consequence, serum phosphorus lowering appears to be a key therapeutic goal. In addition to optimal dialysis treatment and dietary restrictions, oral phosphate binders are the treatment of choice in patients with hyperphosphataemia [7].

Calcium acetate/magnesium carbonate (CaMg) is a combination phosphate binder. Both components separately or magnesium carbonate together with calcium carbonate are already well-established phosphate-lowering agents [8–18]. As high doses of phosphate binders are often required to achieve sufficient phosphate reduction, the risk of hypercalcaemia must be considered when using a pure calcium salt as a phosphate binder. Calcium–magnesium combined preparations are effective alternatives because the proportion of calcium is reduced compared with drugs containing calcium salts only, limiting the risk of hypercalcaemia and of a continuously positive calcium balance [19]. A possible further advantage of a calcium–magnesium

combined preparation is that increased serum magnesium levels have been associated in dialysis patients with beneficial effects such as reduced vascular calcification and improved survival [20–25]. However, only one prospective study, in which intima media thickness was investigated in a small number of patients, provides indirect supporting evidence for reduced vascular calcification [26] with magnesium supplementation.

A phosphate binder combining a reduced calcium exposure and the possible beneficial effect of controlled magnesium administration, potentially offering the double advantage of favourable gastrointestinal tolerance and positive cardiovascular effects, seemed worthwhile to investigate for its phosphorus-lowering capacity in comparison with a well-established drug in a large-scale controlled randomized study for the first time.

Materials and methods

Study population

Patients aged 18–85 years, stable, without serious illness, on 4–6 h haemodialysis (HD) or online haemodiafiltration (HDF) 3× per week for at least 3 months were enrolled in this study. The main eligibility criteria were not taking any magnesium- or calcium-containing supplement, serum phosphorus ≥ 1.78 mmol/L (≥ 5.5 mg/dL), serum calcium ≤ 2.6 mmol/L (≤ 10.4 mg/dL) and serum magnesium ≤ 1.5 mmol/L (≤ 3.65 mg/dL) after washout of phosphate binders (detailed inclusion and exclusion criteria are provided in Supplementary Table 1). Thirty-six dialysis centres in five countries (Germany, Poland, Portugal, Romania and Spain) participated in this study. The study was conducted in conformity with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and the Declaration of Helsinki. The protocol and informed consent form were approved by the responsible Ethics Committees. The study was registered at the European clinical trial database: EudraCT No.: 2006-002589-20.

Study procedure and study design

This prospective, controlled, randomized, multicentre, investigator-masked, parallel-group study compared tolerability and efficacy of two different oral phosphate binder treatments (CaMg and sevelamer-HCl) for 24 weeks in HD or online HDF patients. The primary endpoint of this trial was the exploration of the efficacy of CaMg compared with sevelamer-HCl as an active control. The primary target variable was serum phosphorus at Week 25. After a washout/run-in phase of 2 to 3 weeks, during which all phosphate binders had to be discontinued and all patients were switched to the study dialysis fluid composition (dialysate calcium of 1.5 or 1.25 mmol/L, dependent on prior prescription, and dialysate magnesium of 0.5 mmol/L) for at least 2 weeks, patients were randomized in a 1:1 ratio (Figure 1A). Randomization was central via Fax and stratified according to the dialysis mode (HD vs online HDF). The dialysate calcium composition was constant throughout the study at either 1.25 or 1.5 mmol/L. Only those patients being treated with a dialysate of 1.25 mmol/L during the study could be switched to a dialysate of 1.5 mmol/L in the event of hypocalcaemia.

Study medication

Patients received one of the two study medications: calcium acetate 435 mg containing 110 mg elemental calcium combined with magnesium carbonate 235 mg containing 60 mg elemental magnesium (OsvaRen[®]) or sevelamer-HCl 800 mg (Renagel[®]) for 24 weeks. Blinding of the study medication was virtually impossible, so that an 'investigator-masked' approach was chosen: the trial medication was packed in opaque blister strips and only administered by the study nurse whereby the investigator and other site staff was masked to trial medication. Furthermore, the primary efficacy parameter (serum phosphorus) was determined in a central

laboratory blinded to treatment allocation as were all other persons involved in the trial.

Patient compliance with the treatment was checked weekly from patients' diary entries, by counting of used and unused tablets and by the on-site study monitor dispensing cards. Starting dose of study drugs was at least four tablets per day. Thereafter, following each laboratory result and depending on individual dietary intake, the dose was increased by one to three tablets per day (i.e. one to two tablets per meal) in order to reduce serum phosphorus levels below 1.78 mmol/L (5.5 mg/dL) in the absence of hypercalcaemia or hypermagnesaemia. The number of tablets was prescribed on an individual basis according to the estimated phosphate content of each meal. Regular dietary advice took place prior to the start of and throughout the study.

Study parameters

The primary efficacy parameter was serum phosphorus at Week 25. Secondary efficacy parameters were serum calcium and magnesium at Week 25; further efficacy parameters were number of visits with serum phosphorus ≤ 1.78 mmol/L (≤ 5.5 mg/dL) and ≤ 1.45 mmol/L (≤ 4.49 mg/dL), serum calcium level within the Kidney Disease Outcome Quality Initiative (K/DOQI) recommendation of 2.10 to 2.37 mmol/L (8.41–9.50 mg/dL) and number of visits with a serum calcium and magnesium above [upper limit of normal (ULN)] and below [lower limit of normal (LLN)] the normal range, as well as their respective area under the curve (AUC). Other parameters measured included intact parathormone (iPTH), actual bicarbonate, base excess, low-density lipoprotein (LDL)-cholesterol and potassium. Study medication intake (number of ingested tablets per day) was recorded. Ten visits took place at weekly (until Week 5), fortnightly (Weeks 5–9) and four-weekly intervals (Weeks 9–25).

Tolerability was assessed by means of adverse event profile [adverse event (AE); serious adverse event (SAE)], safety laboratory parameters, electrocardiogram (ECG) and vital signs. Blood gas analyser measurements were taken at the bedside; screening values of serum P, Ca, Mg and iPTH were assessed at the local laboratories of the trial centres. All other laboratory parameter measurements were performed at the central laboratory. A Gastrointestinal Quality of Life Index (GIQLI) validated for gastrointestinal disease [27] was evaluated five times during the study.

Statistical analysis

The following non-inferiority hypothesis was tested: H_0 : serum phosphorus level under CaMg is more than 0.15 mmol/L (0.46 mg/dL) higher than serum phosphorus level under sevelamer-HCl vs H_1 : serum phosphorus level under CaMg is up to 0.15 mmol/L higher, equal or lower than serum phosphorus level under sevelamer-HCl (a Δ of 0.15 mmol/L assumes no clinical difference [28]).

This hypothesis was tested using the principle of 'confidence interval inclusion'. The one-sided 97.5% confidence interval was calculated using an analysis of covariance model including factors for study treatment, centre (pooled), baseline values, dialysate calcium concentration and use of vitamin D and of cinacalcet as covariates as these factors may have a significant influence on the final results.

As the sample size in each treatment group was 100 (a total sample size of 200), a two-group one-sided *t*-test at a 2.5% significance level had 80% power to reject the null hypothesis that the difference in means of serum phosphorus between CaMg and sevelamer-HCl at Week 25 is >0.15 mmol/L. This was based on the assumptions that the expected difference in means is -0.05 mmol/L and the common standard deviation is 0.5 mmol/L, as in previous research reports. To allow for a dropout rate of about 20% for the per-protocol analysis, a total sample size of 248 patients was suggested.

Response rates were tested using a logistic regression model. The number of visits was tested using Wilcoxon rank-sum tests. All other secondary and further efficacy endpoints were tested using the same analysis of covariance (ANCOVA) model as for the primary endpoint. Baseline characteristics were tested using *t*-tests or chi-square tests depending on the distribution of the data. These tests were carried out at a two-sided significance level α of 5%.

The main population for the confirmative analysis of the primary efficacy variable was the per-protocol set (PPS), i.e. all patients who were ran-




Fig. 1. (A) Study design and procedure. (B) CONSORT diagram demonstrating patient flow including analysis sets.

Table 1. Patients' demographics, baseline characteristics (PPS, $N = 204$), screening laboratory values and covariate disposition at baseline (data given as mean \pm SD, N or %)

| Parameter | CaMg | Sevelamer-HCl | P-value |
|--|---------------------|---------------------|---------|
| | ($N = 105$) | ($N = 99$) | |
| Age (years) | 59.2 \pm 13.72 | 55.9 \pm 11.75 | 0.0641 |
| Gender N (%) | | | |
| Female | 49 (46.7) | 48 (48.5) | 0.6554 |
| Male | 56 (53.3) | 51 (51.5) | |
| Weight (kg) | 73.8 \pm 13.7 | 74.9 \pm 12.4 | 0.5419 |
| Height (cm) | 165.4 \pm 8.1 | 166.9 \pm 8.8 | 0.1980 |
| BMI (kg/m ²) | 27.0 \pm 4.6 | 27.0 \pm 3.8 | 0.8857 |
| Dialysis vintage (years) | 4.9 \pm 3.9 | 5.1 \pm 4.2 | 0.6777 |
| Primary diagnosis N (%) ^a | | | |
| Primary chronic glomerulonephritis N (%) | 21 (20.0) | 24 (24.2) | 0.4652 |
| Pylonephritis/interstitial nephritis N (%) | 20 (19.0) | 15 (15.2) | 0.4607 |
| Hypertensive nephropathy/vascular disease N (%) | 12 (11.4) | 11 (11.1) | 0.9429 |
| Secondary glomerulonephritis/systemic diseases, including diabetes N (%) | 16 (15.2) | 19 (19.2) | 0.4541 |
| Familiar/hereditary renal diseases N (%) | 11 (10.5) | 16 (16.2) | 0.2311 |
| Aetiology unknown N (%) | 20 (19.0) | 11 (11.1) | 0.1145 |
| Other N (%) | 6 (5.7) | 7 (7.1) | 0.6918 |
| Screening laboratory parameters | | | |
| Serum phosphorus N (mmol/L) | 2.10 \pm 0.54 | 2.10 \pm 0.59 | 0.9246 |
| Total serum calcium N (mmol/L) | 2.14 \pm 0.25 | 2.18 \pm 0.21 | 0.3226 |
| Serum magnesium N (mmol/L) | 1.20 \pm 0.29 | 1.23 \pm 0.28 | 0.5236 |
| Serum iPTH N (pg/mL) | 382.90 \pm 199.07 | 338.18 \pm 180.09 | 0.0946 |
| Kt/V | 1.5 \pm 0.24 | 1.5 \pm 0.22 | 0.4871 |
| Disposition of covariates at baseline N (%) | | | |
| Vitamin D ₃ (any form) | 40 (38.1) | 29 (29.3) | 0.1841 |
| Calcimimetics | 9 (8.6) | 9 (9.1) | 0.8960 |
| Dialysis type | | | |
| Haemodialysis | 97 (92.4) | 85 (85.6) | |
| Online HDF | 8 (7.6) | 14 (14.4) | 0.1334 |
| Dialysis fluid type (Calcium) | | | |
| other | 2 (1.9) | 1 (1.01) | |
| 1.25 mmol/L | 41 (39.1) | 30 (30.3) | |
| 1.50 mmol/L | 62 (59.1) | 68 (68.7) | 0.3430 |

^aMore than one answer could be given.

domized and completed the study per protocol. All analyses of secondary and further efficacy endpoints were based on the full analysis set (FAS) using the Last Observation Carried Forward (LOCF) method. The FAS consisted of all patients who were randomized, took study medication and had at least one subsequent efficacy evaluation. The safety parameter evaluation was performed on the safety population (SAS), which consisted of all randomized patients who took study medication. Data are presented as means \pm SD, figures are presented as means \pm SEMs. For differences between groups, the least square means, i.e. the differences within-group means, appropriately adjusted for the other factors in the model, are given. As for all evaluations, the factors pooled centre and baseline value were significant, only the ones in addition to these are mentioned in the Results section.

Results

Patients and baseline characteristics

The first patient entered the study on 26 November 2007, and the last patient completed the study on 25 March 2009. Three hundred and twenty-six haemodialysis patients were enrolled in order to reach the number of patients described above. Seventy-one patients were failures during washout/run-in, the majority due to unexpectedly low serum phosphorus levels measured between screening and the third

week of washout ($N = 45$). Finally, 255 patients were randomized, and 204 patients completed the study per protocol (CaMg, $N = 105$; sevelamer-HCl, $N = 99$, see Figure 1B, CONSORT diagram [29]).

The most frequent reasons for dropout after randomization were withdrawal of informed consent (CaMg: $N = 9$, sevelamer-HCl: $N = 19$) and adverse events (CaMg: $N = 4$, sevelamer-HCl: $N = 9$) (Figure 1B).

Baseline demographics, screening laboratory parameters and baseline covariates of the study patients are shown in Table 1. There were no statistically significant differences in any of the parameters between the two groups. There were also no differences between groups with regards to co-morbidities, including diabetes mellitus (24.8% in the CaMg group vs 20.2% in the sevelamer-HCl group, $P = 0.4360$) and the use of prior and concomitant medications including vitamin D and calcimimetics. The percentage of patients receiving any form of vitamin D was higher at baseline in the CaMg group (CaMg: 38.1%; sevelamer-HCl: 29.3%) and did not change significantly in either group. Also, the use of calcimimetics did not change over time.

The mean percentage compliance with study medication intake was close to 100% in both groups. Average




Fig. 2. (A) Study medication intake per day and group over time in the CaMg group ($n = 101$) and the Sevelamer-HCl group ($n = 90$) (PPS); $P = 0.0420$ (ANOVA). (B) Time course of serum phosphorus over 24 weeks for the CaMg group ($n = 105$); and the sevelamer-HCl group ($n = 99$) (PPS).

daily study medication intake was slightly but significantly higher in the sevelamer-HCl group at Week 25 (CaMg: 7.3 ± 3.03 ; sevelamer-HCl: 8.1 ± 2.87 tablets/day; $P = 0.0420$) (Figure 2A).

Primary efficacy endpoint serum phosphorus

With both study treatments, significant reductions in serum phosphorus were achieved. The mean reduction at Week 25 was not different between the CaMg group (-0.761 ± 0.5805 mmol/L; -2.356 ± 1.7972 mg/dL) and the sevelamer-HCl group (-0.711 ± 0.5850 mmol/L; -2.201 ± 0.8111 mg/dL). Serum phosphorus level achieved after 25 weeks was 1.704 ± 0.4806 mmol/L (5.276 ± 1.4879 mg/dL) in the CaMg group in comparison with 1.769 ± 0.6066 mmol/L (5.477 ± 1.8780 mg/dL) in the sevelamer-HCl group (Figure 2B; Table 2) with a treatment difference of -0.0693 mmol/L (-0.2146 mg/dL). The corresponding one-sided 97.5% confidence interval was $[-\infty, 0.0692$ mmol/L; 0.2142 mg/dL]. As the non-inferiority margin of 0.15 mmol/L was not part of this confidence interval, the non-inferiority of CaMg against sevelamer-HCl was statistically proven (Table 2).

Further phosphorus-related efficacy parameters

The AUC of serum phosphorus was significantly lower in the CaMg group compared with the sevelamer-HCl group with a difference of -24.5264 mmol/L \times days (-75.9331 mg/dL \times days), ($P = 0.0042$). Furthermore, the number of visits when target serum phosphorus levels (≤ 1.78 mmol/L; 5.51 mg/dL and ≤ 1.45 mmol/L; 4.49 mg/dL) were reached and the time to reach these targets were significantly higher and shorter in the CaMg group in comparison with the sevelamer-HCl group (Table 2).

Calcium-related efficacy parameters

No significant differences for ionized serum calcium were seen between the groups (Table 3; Figure 3A). During the course of the study, total serum calcium increased significantly in the CaMg group, while no changes were observed in the sevelamer-HCl group (Table 3; Figure 3B). The treat-

Table 2. Serum phosphorus: values at baseline and at week 25, changes from baseline, area under the curve (AUC) until Week 25, number of visits where target serum phosphorus (sP) was reached and time to reach target values

| Parameter | CaMg | | Sevelamer-HCl | | P-value |
|--|------|-----------------------|---------------|-----------------------|-----------------|
| | N | (Mean \pm SD) | N | (Mean \pm SD) | |
| Serum phosphorus (mmol/L) ^a | | | | | |
| Baseline | 105 | 2.464 ± 0.4930 | 99 | 2.480 ± 0.4704 | na ^c |
| Week 25 | 105 | 1.704 ± 0.4806 | 99 | 1.769 ± 0.6066 | na ^c |
| Change at Week 25 | 105 | -0.761 ± 0.5805 | 99 | -0.711 ± 0.5850 | na ^c |
| Treatment difference (LS-means) [confidence interval] | | | | | |
| AUC of serum phosphorus (mmol/L \times days) ^b | 122 | 298.935 ± 72.0315 | 122 | 323.914 ± 81.2415 | |
| Treatment difference (LS-means) [confidence interval] | | | | | 0.0042 |
| No. of visits (N) target sP (≤ 1.78 mmol/L) reached ^b | 122 | 4.91 ± 3.275 | 122 | 3.96 ± 3.363 | 0.0198 |
| No. of visits (N) target sP (≤ 1.45 mmol/L) reached ^b | 122 | 2.65 ± 2.784 | 122 | 1.81 ± 2.420 | 0.0067 |
| Time (days) to target sP (≤ 1.78 mmol/L) ^b | 122 | 16 | 122 | 30 | 0.0018 |
| Time (days) to target sP (≤ 1.45 mmol/L) ^b | 122 | 57 | 122 | 140 | 0.0052 |

^a(PPS, $N = 204$).

^b(FAS, $N = 244$).

^cNot applicable.

Table 3. Serum calcium and magnesium baseline values, changes from baseline values at Week 25 and number of visits > ULN and < LLN, as well as above and below K/DOQI range (for Ca) (FAS, $N = 244$)

| Parameter | CaMg | | Sevelamer-HCl | | P-value |
|---|----------|---------------------------|---------------|--------------------|---------|
| | <i>N</i> | (Mean \pm SD) | <i>N</i> | (Mean \pm SD) | |
| Ionized calcium (mmol/L) | | | | | |
| Baseline | 113 | 1.071 \pm 0.1608 | 112 | 1.076 \pm 0.1306 | |
| Week 25 | 120 | 1.104 \pm 0.1210 | 119 | 1.113 \pm 0.1063 | |
| Change at Week 25 | 112 | 0.036 \pm 0.1702 | 110 | 0.036 \pm 0.1369 | |
| Treatment difference (LS-means) [confidence interval] | | -0.0015 [-0.0294, 0.0264] | | | 0.9173 |
| Total serum calcium (mmol/L) | | | | | |
| Baseline | 122 | 2.148 \pm 0.2288 | 122 | 2.185 \pm 0.1820 | |
| Week 25 | 122 | 2.219 \pm 0.1565 | 122 | 2.189 \pm 0.1574 | |
| Change at Week 25 | 122 | 0.071 \pm 0.1790 | 122 | 0.004 \pm 0.1522 | |
| Treatment difference (LS-means) [confidence interval] | | 0.0477 [0.0162, 0.0793] | | | 0.0032 |
| No. of visits Ca > ULN (2.6 mmol/L) | 122 | 0.11 \pm 0.460 | 122 | 0.07 \pm 0.563 | 0.2374 |
| No. of visits Ca < LLN (2.2 mmol/L) | 122 | 4.31 \pm 3.695 | 122 | 4.55 \pm 3.827 | 0.6839 |
| No. of visits Ca > K/DOQI range (2.37 mmol/L) | 122 | 1.81 \pm 2.881 | 122 | 1.25 \pm 2.412 | 0.1005 |
| No. of visits Ca < K/DOQI range (2.10 mmol/L) | 122 | 2.23 \pm 2.911 | 122 | 2.38 \pm 3.178 | 0.4809 |
| Serum magnesium (mmol/L) | | | | | |
| Baseline | 122 | 0.993 \pm 0.1544 | 122 | 0.996 \pm 0.1613 | |
| Week 25 | 122 | 1.297 \pm 0.2547 | 122 | 1.039 \pm 0.1851 | |
| Change at Week 25 | 122 | 0.304 \pm 0.2285 | 122 | 0.043 \pm 0.1453 | |
| Treatment difference (LS-means) [confidence interval] | | 0.2597 [0.2137, 0.3056] | | | <0.0001 |
| No. of visits Mg > ULN (1.05 mmol/L) | 122 | 7.86 \pm 2.514 | 122 | 4.10 \pm 3.797 | <0.0001 |
| No. of visits Mg < LLN (0.65 mmol/L) | 122 | 0.04 \pm 0.237 | 122 | 0.04 \pm 0.237 | 1.0000 |

ment difference was 0.0477 mmol/L (0.1913 mg/dL) ($P = 0.0032$).

Response rates at Week 25 (K/DOQI range: serum calcium between 2.10 and 2.37 mmol/L; 8.41 and 9.50 mg/dL) [30] were also not different between CaMg and Sevelamer-HCl, i.e. 65.6% vs 60.7%, respectively ($P = 0.3158$). The number of visits of serum Ca > ULN (>2.6 mmol/L; >10.42 mg/dL) and serum Ca < LLN (<2.2 mmol/L; <8.82 mg/dL), as well as above and below the K/DOQI ranges, which are summarized in Table 3, also did not differ. All total serum calcium-related evaluations have been repeated with albumin corrected total serum calcium, confirming the above-mentioned results (data not shown).

Magnesium-related efficacy parameters

Serum magnesium values at baseline and changes from baseline, number of episodes of Mg > ULN (>1.05 mmol/L; 2.55 mg/dL) and of Mg < LLN (<0.65 mmol/L; 1.58 mg/dL) after 24 weeks of treatment are summarized in Table 3. During the course of the study, serum magnesium increased significantly in the CaMg group, while only a slight increase in the sevelamer-HCl group was observed (Figure 4). The treatment difference was 0.2597 mmol/L (0.6313 mg/dL) ($P < 0.0001$). The number of episodes of Mg > ULN were higher in the CaMg group compared with the sevelamer-HCl group. In both treatment groups, nearly no episodes of Mg < LLN (0.04 ± 0.237 for both groups) occurred during the course of the study.

iPTH and alkaline phosphatase

iPTH decreased during the course of the study in both groups until Week 9 and then increased significantly in the sevelamer-HCl group but without any further signifi-

cant change in the CaMg group (Table 4, Figure 5). At Week 25, the treatment difference was -64.4773 pg/mL which was statistically significant ($P = 0.0085$). The AUC of iPTH was also significantly lower in the CaMg group (data not shown). Alkaline phosphatase (AP) increased significantly in both groups until Week 9 ($P < 0.0001$ for both groups). Thereafter, AP increased like iPTH in the sevelamer-HCl group but not in the CaMg group. At Week 25, the treatment difference was statistically significantly different ($P < 0.0001$) with the respective mean difference of -24.0067 U/L (Table 4).

Other biochemical parameters

Values of other biochemical parameters are summarized in Table 5. After 25 weeks, a significant difference in actual bicarbonate and base excess was noted between groups. In addition, LDL-cholesterol decreased significantly in the sevelamer-HCl group. No change was observed in the CaMg group. Neither high-density lipoprotein-cholesterol nor triglycerides showed any significant change within groups or difference between groups (data not shown). Serum potassium increased in the CaMg group and stayed almost the same in the sevelamer-HCl group.

Gastrointestinal quality of life index

The GIQLI did not change over time and was not different between groups.

Safety parameters

Adverse events. The number of patients with AEs and SAEs were comparable in both treatment groups. There was no difference regarding occurrence of any AEs between groups. In the CaMg group, fewer patients experi-




Fig. 3. (A) Time course of ionized serum calcium of the CaMg group ($n = 120$) and of the sevelamer-HCl group ($n = 119$) (FAS); $P = 0.9173$ (ANCOVA). (B) Time course of total serum calcium of the CaMg group ($n = 122$) and of the sevelamer-HCl group ($n = 122$) (FAS); $P = 0.0032$ (ANCOVA).

enced AEs leading to study withdrawal (Figure 1B). The intensity of about 80% of AEs was classified as mild. A total of 16.1% AEs in the CaMg group and 19.7% in sevelamer-HCl-treated patients were classified as moderate; 4.0% and 2.5% of AEs, respectively, were judged to be severe. None of the SAEs was judged to be related; their number was slightly lower in the CaMg group. Related gastrointestinal AEs were more frequently noted in the sevelamer-HCl group (23.6% of subjects vs 13.6% in the CaMg group). Related 'metabolism disorders', such as electrolyte disturbances, were more frequent in the CaMg group, most of them were episodes of asymptomatic hypermagnesaemia reported as related AE by the treating physician (8.8% vs 2.4% in the sevelamer-HCl group). In none of the other AEs was there any difference between groups, particularly in relation to cardiac dysrhythmia, muscle spasm or cramps.

Other haematology, biochemistry parameters, vital signs. Mean \pm SD values of haematology, bedside laboratory, Kt/V and serum chemistry parameters fluctuated within expected normal variation in both treatment groups. The same applied to vital signs and ECG.




Fig. 4. Time course of serum magnesium of the CaMg group ($n = 122$) and of the sevelamer-HCl group ($n = 122$) (FAS); $P < 0.0001$ (ANCOVA).

Discussion

The main purpose of this study was to determine whether treatment of hyperphosphataemia could be achieved efficiently with a phosphate binder combining calcium and magnesium salts in comparison with a well-established non-calcium-containing phosphate binder. Confirming the study hypothesis, serum phosphorus levels at Week 25 were at least as efficiently lowered with the use of CaMg as with sevelamer-HCl. Furthermore, when serum phosphorus control over time was evaluated, it was significantly lower in the group assigned to the CaMg phosphate binder ($P = 0.0042$). In addition, both predefined target ranges of serum phosphorus (≤ 1.78 mmol/L; 5.51 mg/dL and ≤ 1.45 mmol/L; 4.49 mg/dL) were significantly more often reached with CaMg ($P = 0.0198$ and $P = 0.0067$, respectively). Furthermore, the time to target was shorter with CaMg; as an example, the time needed for 50% of patients to achieve a target of serum phosphorus ≤ 1.45 mmol/L was reduced by 84 days. Taken together, these results suggest that the control of serum phosphorus levels could be attained more easily with CaMg. The number of tablets needed to achieve these results was slightly lower in the CaMg group and overall comparable or lower than in other studies using calcium salts [9,10,12]. Also, the described phosphate-lowering effect in this study is comparable with [10,31] or superior to [9,10,32] other studies, in which pure calcium salts were investigated in comparison with sevelamer-HCl. This is in line with recent systematic reviews [33,34]. However, in general it is a challenge to control serum phosphorus adequately [5].

Sevelamer was chosen as a comparator because one of the discussed advantages of sevelamer use is its lack of producing a positive calcium burden, an observation that was repeatedly linked to a decreased rate of calcification [31,35–38]. In this study with a calcium and magnesium-containing phosphate binder, we did not find any difference in ionized serum calcium levels, a small, albeit statistically significant difference in total serum calcium of 0.0477 mmol/L (0.1908 mg/dL) and very few, less than one, hypercalcaemic episodes with no difference between groups. In contrast, in

Table 4. Serum iPTH and alkaline phosphatase: values at baseline, week 9 and 25 and changes from baseline (FAS, $N = 244$)

| Parameter | CaMg | | Sevelamer-HCl | | P-value |
|---|------|--------------------------------|---------------|----------------------|---------|
| | N | (Mean \pm SD) | N | (Mean \pm SD) | |
| Serum iPTH (pg/mL) | | | | | |
| Baseline | 119 | 450.84 \pm 273.494 | 118 | 438.97 \pm 238.112 | |
| Week 9 | 118 | 361.25 \pm 278.526 | 112 | 357.71 \pm 201.909 | |
| Change at Week 9 | 115 | -85.28 \pm 195.308 | 108 | -72.69 \pm 154.429 | 0.6059 |
| Week 25 | 118 | 337.20 \pm 266.357 | 112 | 384.67 \pm 226.349 | |
| Change at Week 25 | 115 | -109.24 \pm 229.903 | 108 | -43.98 \pm 171.438 | |
| Treatment difference (LS-means) [confidence interval] | | -64.4773 [-112.3087, -16.6459] | | | 0.0085 |
| Significant covariate factor | | | | | |
| Intake of calcimimetics | | | | | 0.0211 |
| Serum alkaline phosphatase (U/L) | | | | | |
| Baseline | 122 | 100.39 \pm 49.689 | 122 | 93.00 \pm 38.384 | |
| Week 9 | 116 | 108.44 \pm 52.237 | 104 | 120.42 \pm 52.675 | |
| Change at Week 9 | 116 | 8.85 \pm 23.523 | 104 | 25.32 \pm 27.006 | <0.0001 |
| Week 25 | 116 | 106.84 \pm 53.803 | 105 | 125.93 \pm 53.479 | |
| Change at Week 25 | 116 | 7.26 \pm 32.438 | 105 | 30.90 \pm 34.101 | |
| Treatment difference (LS-means) [confidence interval] | | -24.0067 [-32.8963, -15.1175] | | | <0.0001 |

studies where pure calcium salts were administered, a serum calcium increase of up to 0.15 mmol/L (0.6 mg/dL) was observed [9,10,31,32]. The number of hypercalcaemic episodes was also much more pronounced in other studies [10,31,35,37,39]. These results may indicate a clinically meaningful reduction in calcium burden, as the daily elemental calcium applied in this study was only between 25% and 50% of other studies with pure calcium salts [10,12,15,40]. Nevertheless, it was beyond the scope of this study to assess calcium balance, and specific trials would be needed to address this question.

Magnesium-based phosphate binders have been used in the past with excellent results [14–16,24]. However, there always has been some apprehension related to the potential negative consequences of a rise in serum magnesium. The observed increase in serum magnesium in the CaMg group was expected based on past experience [19] and comparable with other studies [15,41–44]. In our study, a plateau was reached at around 7–9 weeks, which was not associated with any clinical side effects, especially not with an appar-

ent increased frequency of diarrhoea. An elevation of serum magnesium levels is common in patients on haemodialysis [21,25,45,46], even when not treated with a magnesium-containing phosphate binder. Serum magnesium levels are largely dependent on dialysis fluid concentration as the only possibility to eliminate magnesium is via dialysis once residual renal function has disappeared [46–48]. In our study population, mean serum magnesium level was already elevated at screening (Table 1). More than 40% of patients had been treated with a dialysis fluid magnesium concentration of 1.00 mmol/L (2.43 mg/dL); their mean serum magnesium concentration was 1.34 mmol/L, which was considerably higher than the mean Mg concentrations at Week 25 in the CaMg group. Therefore, the general recommendation to use a dialysis fluid with a Mg concentration of 0.5 mmol/L or lower, independent of the phosphate binder used, might be considered. However, the optimal dialysate Mg concentration can only be established by specifically designed studies. Magnesium has been described as having a much wider therapeutic range than calcium, and as such hypermagnesaemia at levels up to 1.5 mmol/L (3.65 mg/dL) is not associated with clinical effects [14,43]. Neuromuscular side effects may only become apparent at levels of 2 to 3 mmol/L (4.86 to 7.29 mg/dL) [23].

There is concern that increased serum magnesium levels may have an effect on bone in dialysis patients dependent on its PTH-lowering effect as well as independently of it (discussed in [23]). It was not the aim of this study to investigate bone histology, but identifying the role of magnesium in the development of bone mineral disorders remains an important open question.

On the other hand, it is also important to emphasize the other ‘face of the coin’: magnesium is a potent inhibitor of the calcification process, as has been shown in vitro [49] and in experimental animal studies which demonstrated that experimental magnesium deficiency is related to the development of dystrophic calcifications [50]. In addition, also in CKD 5 and the general population, mildly elevated magnesium levels have been associ-




Fig. 5. Time course of iPTH of the CaMg group ($n = 118$) and of the sevelamer-HCl group ($n = 112$) (FAS), $P = 0.0085$ (ANCOVA); within-group changes CaMg: *Week 9 vs baseline: $P < 0.0001$, **Week 25 vs Week 9: $P = 0.0768$; within-group changes sevelamer-HCl: * Week 9 vs baseline: $P = 0.0090$, ** Week 25 vs Week 9: $P = 0.0242$.

Table 5. Actual bicarbonate, base excess, LDL-cholesterol and potassium at baseline, changes from baseline and at Week 25 (FAS, *N* = 244)

| Parameter | CaMg | | Sevelamer-HCl | | P-value |
|---|----------|----------------------------|---------------|-----------------|---------|
| | <i>N</i> | (Mean ± SD) | <i>N</i> | (Mean ± SD) | |
| Actual bicarbonate (mmol/L) | | | | | |
| Baseline | 106 | 21.086 ± 2.6587 | 102 | 21.588 ± 3.4209 | |
| Week 25 | 117 | 22.496 ± 3.3095 | 114 | 21.086 ± 4.0833 | |
| Change at Week 25 | 106 | 1.500 ± 3.1117 | 101 | -0.823 ± 4.3323 | <0.0001 |
| Treatment difference (LS-means) [confidence interval] | | 1.8435 [0.9462, 2.7408] | | | <0.0001 |
| Base excess | | | | | |
| Baseline | 110 | -3.729 ± 2.9518 | 107 | -3.133 ± 3.6341 | |
| Week 25 | 121 | -2.340 ± 3.4567 | 118 | -3.702 ± 4.2831 | |
| Change at Week 25 | 110 | 1.594 ± 3.2531 | 106 | -0.853 ± 4.3851 | <0.0001 |
| Treatment difference (LS-means) [confidence interval] | | 1.9466 [1.0171, 2.8761] | | | <0.0001 |
| LDL-cholesterol (mg/dL) | | | | | |
| Baseline | 122 | 112.71 ± 31.717 | 122 | 115.03 ± 30.346 | |
| Week 25 | 116 | 110.19 ± 30.060 | 105 | 87.17 ± 27.870 | |
| Change at Week 25 | 116 | -2.85 ± 21.458 | 105 | -28.09 ± 25.746 | |
| Treatment difference (LS-means) [confidence interval] | | 23.5287 [17.9405, 29.1169] | | | <0.0001 |
| Potassium (mmol/L) | | | | | |
| Baseline | 122 | 5.50 ± 0.967 | 122 | 5.36 ± 0.732 | |
| Week 25 | 118 | 5.79 ± 0.793 | 112 | 5.39 ± 0.807 | |
| Change at Week 25 | 118 | 0.27 ± 0.968 | 112 | 0.03 ± 0.776 | |
| Treatment difference (LS-means) [confidence interval] | | 0.3192 [0.1250, 0.5134] | | | 0.0014 |

ated with benefits, such as reduced cardiovascular calcifications, reduced hypertension and reduced mortality [23,24]. Generally, CaMg was well tolerated with an AE profile consistent with the co-morbidities of a dialysis patient. AEs definitively related to the study drug were significantly more frequent in the sevelamer-HCl group and were gastrointestinal disorders; otherwise, except for episodes of hypermagnesaemia, no difference was noted between groups in particular regarding hyper- and hypocalcaemia, indicating an overall favourable tolerability profile of CaMg.

Reflecting the KDIGO CKD-MBD guideline [7], CaMg offers an alternative phosphate binder option as switching from pure calcium salts to CaMg may be a possibility restricting the dose of calcium.

In conclusion, CaMg was non-inferior compared with a well-established non-calcium-containing phosphate binder at lowering serum phosphorus in this controlled, randomized, investigator-masked study in 255 patients. There was a small increase in total serum calcium and no change in ionized calcium. CaMg led to an asymptomatic increase in serum magnesium and had a good tolerability profile.

Supplementary data

Supplementary data is available online at <http://ndt.oxfordjournals.org>.

Acknowledgements. We wish to thank all the participants and all contributors to the CALMAG study, the study coordinators, medical directors and nurses for their dedication and hard work, and we are grateful to the patients who took part in the study: **Germany:** Bueschges-Seraphin B (Fuerth), Dellanna F (Duesseldorf), Ketteler M (Coburg), Leidig M (Nuernberg), Weinreich T (Villingen-Schwennigen); **Poland:** Benedyk-Lorens E (Krakow), Figarska M (Zamość), Kaczmarek A (Pleszew), Kaniowski M (Kolo), Kloczkowska-Trzcinecka M (Piotrk Tryb), Krocak M

(Sieradz), Kubit P (Żywiec), Mendel M (Slupca), Pośpiech K (Tarnowskie Gory), Śliwicka D (Sochaczew), Stanek-Piotrowska M (Wroclaw), Swatowski A (Kraśnik), Woch W (Sącz); **Portugal:** Miranda V (Maia), Ponce P (Almada), Silva M (Vila Nova de Gaia), Romania: Boca I (Sibiu), Carastoian N (Giurgiu), Covic A (Iasi), Ghenu A (Targoviste), Macaveiu R (Brasov), Mircescu G, Klein C (Bucaresti), Mota E (Craiova); **Spain:** de Francisco ALM (Santander), Jofre Ibanez R, Herrero JA, Berlanga JR, Villaverde M (Madrid), Mallorca AR, Martin-Malo A (Cordoba), Montenegro J (Bilbao). This study was supported by Fresenius Medical Care Deutschland GmbH, Germany.

Conflict of interest statement. This study was presented as an abstract at the annual meeting of the American Society of Nephrology; San Diego, CA; 27 October to 1 November 2009; furthermore, the results presented in this paper have not been published previously in whole or part. A.L.M. de F. is an advisor to Amgen and Roche and has received speakers' honoraria from Abbott and Gambro. M.L. is on advisory boards of Vifor and has received speakers' honoraria from Fresenius Medical Care, Roche and Shire. A.C. is a consultant to Roche, Amgen, AFFYMAX and Fresenius Medical Care. M.K. has received research grant support from Abbott and Amgen and speakers' honoraria from Abbott, Amgen, Fresenius Medical Care, Genzyme and Shire. P.P. serves as the Portuguese Country Medical Representative for Fresenius Medical Care. E. BL. serves as the responsible nephrologist at a Fresenius NephroCare dialysis centre. C.S. and J.P.D. are employees of Fresenius Medical Care Deutschland GmbH, Bad Homburg. No conflict of interest was declared by G.M.

References

- Block GA, Hulbert-Shearon TE, Levin NW *et al.* Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. *Am J Kidney Dis* 1998; 31: 607–617
- Covic A, Kothawala P, Bernal M *et al.* Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. *Nephrol Dial Transplant* 2009; 24: 1506–1523
- Lezaic V, Tirmenstajn-Jankovic B, Bukvic D *et al.* Efficacy of hyperphosphatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification. *Clin Nephrol* 2009; 71: 21–29

4. Wald R, Sarnak MJ, Tighiouart H *et al.* Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. *Am J Kidney Dis* 2008; 52: 531–540
5. Tentori F, Blayney MJ, Albert JM *et al.* Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis* 2008; 52: 519–530
6. Plantinga LC, Fink NE, Melamed ML *et al.* Serum phosphate levels and risk of infection in incident dialysis patients. *Clin J Am Soc Nephrol* 2008; 3: 1398–1406
7. KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease—Mineral and Bone Disorder (CKD-MBD). *Kidney Int* 2009; 76: S1–S130
8. Friedman EA. Calcium-based phosphate binders are appropriate in chronic renal failure. *Clin J Am Soc Nephrol* 2006; 1: 704–709
9. Qunibi WY, Hootkins RE, McDowell LL *et al.* Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renegel Evaluation (CARE Study). *Kidney Int* 2004; 65: 1914–1926
10. Qunibi W, Moustafa M, Muenz LR *et al.* A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renegel Evaluation-2 (CARE-2) study. *Am J Kidney Dis* 2008; 51: 952–965
11. Ring T, Nielsen S, Andersen SP *et al.* Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study. *Nephrol Dial Transplant* 1993; 8: 341–346
12. Schaefer K, Scheer J, Asmus G *et al.* The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. *Nephrol Dial Transplant* 1991; 6: 170–175
13. Delmez JA, Tindira CA, Windus DW *et al.* Calcium acetate as a phosphorus binder in hemodialysis patients. *J Am Soc Nephrol* 1992; 3: 96–102
14. Delmez JA, Kelber J, Norword KY *et al.* Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. *Kidney Int* 1996; 49: 163–167
15. Spiegel DM, Farmer B, Smits G *et al.* Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. *J Ren Nutr* 2007; 17: 416–422
16. Spiegel DM. The role of magnesium binders in chronic kidney disease. *Semin Dial* 2007; 20: 333–336
17. Spiegel DM, Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study. *Hemodial Int* 2009; 13: 453–459
18. Tzanakis IP, Papadaki AN, Wei M *et al.* Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. *Int Urol Nephrol* 2008; 40: 193–201
19. Deuber HJ. Long-term efficacy and safety of an oral phosphate binder containing both calcium acetate and magnesium carbonate in hemodialysis patients. *Nieren-und Hochdruckkrankheiten* 2004; 33: 403–408
20. Tzanakis I, Pras A, Kounali D *et al.* Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium. *Nephrol Dial Transplant* 1997; 12: 2036–2037
21. Ishimura E, Okuno S, Kitatani K *et al.* Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. *Clin Nephrol* 2007; 68: 222–227
22. Ishimura E, Okuno S, Yamakawa T *et al.* Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. *Magnes Res* 2007; 20: 237–244
23. Navarro-Gonzalez JF, Mora-Fernandez C, Garcia-Perez J. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. *Semin Dial* 2009; 22: 37–44
24. Kanbay M, Goldsmith D, Uyar ME *et al.* Magnesium in chronic kidney disease: challenges and opportunities. *Blood Purif* 2009; 1–13. doi:10.1159/000XXXXXX
25. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. *Kidney Int* 1987; 32: 388–394
26. Turgut F, Kanbay M, Metin MR *et al.* Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. *Int Urol Nephrol* 2008; 40: 1075–1082
27. Eypasch E, Williams JI, Wood-Dauphinee S *et al.* Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. *Br J Surg* 1995; 82: 216–222
28. Schmidt-Gayk H. Measurement of calcium, phosphate and magnesium. In: MJ Seibel, SP Robins, JP Bilezikian (eds). *Dynamics of Bone and Cartilage Metabolism*. Burlington, San Diego, London: Academic Press, 2006; 487–505
29. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet* 2001; 357: 1191–1194
30. K/DOQI. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis* 2003; 42: S1–201
31. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int* 2002; 62: 245–252
32. Evenepoel P, Selgas R, Caputo F *et al.* Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. *Nephrol Dial Transplant* 2009; 24: 278–285
33. Tonelli M, Wiebe N, Cullerton B *et al.* Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. *Nephrol Dial Transplant* 2007; 22: 2856–2866
34. Navaneethan SD, Palmer SC, Craig JC *et al.* Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. *Am J Kidney Dis* 2009; 54: 619–637
35. Block GA, Spiegel DM, Ehrlich J *et al.* Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. *Kidney Int* 2005; 68: 1815–1824
36. London GM, Marchais SJ, Guerin AP *et al.* Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. *J Am Soc Nephrol* 2008; 19: 1827–1835
37. Asmus HG, Braun J, Krause R *et al.* Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. *Nephrol Dial Transplant* 2005; 20: 1653–1661
38. Russo D, Miranda I, Ruocco C *et al.* The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. *Kidney Int* 2007; 72: 1255–1261
39. Hutchison AJ, Maes B, Vanwalleghem J *et al.* Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. *Nephron Clin Pract* 2005; 100: c8–19
40. Shaheen FA, Akeel NM, Badawi LS *et al.* Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. *Saudi Med J* 2004; 25: 785–791
41. Oe PL, Lips P, van der MJ *et al.* Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. *Clin Nephrol* 1987; 28: 180–185
42. McIntyre CW, Pai P, Warwick G *et al.* Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. *Clin J Am Soc Nephrol* 2009; 4: 401–409
43. Moriniere P, Vinatier I, Westeel PF *et al.* Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation. *Nephrol Dial Transplant* 1988; 3: 651–656
44. Guillot AP, Hood VL, Runge CF *et al.* The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. *Nephron* 1982; 30: 114–117
45. Saha H, Harmoinen A, Pietila K *et al.* Measurement of serum ionized versus total levels of magnesium and calcium in hemodialysis patients. *Clin Nephrol* 1996; 46: 326–331
46. Navarro-Gonzalez JF. Magnesium in dialysis patients: serum levels and clinical implications. *Clin Nephrol* 1998; 49: 373–378
47. Kelber J, Slatopolsky E, Delmez JA. Acute effects of different concentrations of dialysate magnesium during high-efficiency dialysis. *Am J Kidney Dis* 1994; 24: 453–460

48. Nilsson P, Johansson SG, Danielson BG. Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium. *Nephron* 1984; 37: 25–29
49. Boskey AL, Posner AS. Effect of magnesium on lipid-induced calcification: an in vitro model for bone mineralization. *Calcif Tissue Int* 1980; 32: 139–143
50. van den Broek FA, Beynen AC. The influence of dietary phosphorus and magnesium concentrations on the calcium content of heart and kidneys of DBA/2 and NMRI mice. *Lab Anim* 1998; 32: 483–491

Received for publication: 18.12.09; Accepted in revised form: 30.4.10